NGcGM3 ganglioside: A privileged target for cancer vaccines

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Alonso, Daniel F ^b   Fernandez, Luis E ^a   Gabri, Mariano R ^b   Guthmann, Marcelo D ^c   Gomez, Roberto E ^c   Gold, Silvia ^d   Fainboim, Leonardo ^e   Gomez, Daniel E ^b  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c ELEA Laboratories   (Argentina)

^d Chemo Romikin   (Argentina)

^e HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GANGLIOSIDE; GANGLIOSIDE NGCGM3; GANGLIOSIDE NGCGM3 VERY SMALL SIZE PROTEOLIPOSOME VACCINE; RACOTUMOMAB; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; DRUG DERIVATIVE; GANGLIOSIDE GM3; MONOCLONAL ANTIBODY; N GLYCOLOYLNEURAMINYLLACTOSYLCERAMIDE; N-GLYCOLYLNEURAMINYLLACTOSYLCERAMIDE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; DRUG ERUPTION; DRUG RESEARCH; DRUG TARGETING; ERYTHEMA; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; G(M3) GANGLIOSIDE; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 78650730811     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/814397     Document Type: Review

References (58)

1. Higano C. S., Schellhammer P. F., Small E. J., Burch P. A., Nemunaitis J., Yuh L., Provost N., Frohlich M. W., Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 2009 115 16 3670 3679
2. McNeel D. G., Dunphy E. J., Davies J. G., Frye T. P., Johnson L. E., Staab M. J., Horvath D. L., Straus J., Alberti D., Marnocha R., Liu G., Eickhoff J. C., Wilding G., Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer Journal of Clinical Oncology 2009 27 25 4047 4054
3. Irie R. F., Irie K., Morton D. L., A membrane antigen common to human cancer and fetal calf brain Cancer Research 1976 36 3510 3517
4. Livingston P. O., Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines Immunological Reviews 1995 145 147 166
5. Kirkwood J. M., Ibrahim J. G., Sosman J. A., Sondak V. K., Agarwala S. S., Ernstoff M. S., Rao U., High-dose interferon -2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 Journal of Clinical Oncology 2001 19 9 2370 2380
6. Eggermont A. M. M., Therapeutic vaccines in solid tumours: can they be harmful? European Journal of Cancer 2009 45 12 2087 2090
7. Cheever M. A., Allison J. P., Ferris A. S., Finn O. J., Hastings B. M., Hecht T. T., Mellman I., Prindiville S. A., Viner J. L., Weiner L. M., Matrisian L. M., The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research Clinical Cancer Research 2009 15 17 5323 5337
8. Fernndez L. E., Alonso D. F., Gomez D. E., Vzquez A. M., Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer Expert Review of Vaccines 2003 2 6 817 823
9. Schauer R., Achievements and challenges of sialic acid research Glycoconjugate Journal 2000 17 79 485 499
10. Muchmore E. A., Diaz S., Varki A., A structural difference between the cell surfaces of humans and the great apes American Journal of Physical Anthropology 1998 107 2 187 198
11. Irie A., Koyama S., Kozutsumi Y., Kawasaki T., Suzuki A., The molecular basis for the absence of N-glycolylneuraminic acid in humans Journal of Biological Chemistry 1998 273 25 15866 15871
12. Chou H.-H., Takematsu H., Diaz S., Iber J., Nickerson E., Wright K. L., Muchmore E. A., Nelson D. L., Warren S. T., Varki A., A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence Proceedings of the National Academy of Sciences of the United States of America 1998 95 20 11751 11756
13. Hayakawa T., Satta Y., Gagneux P., Varki A., Takahata N., Alu-mediated inactivation of the human CMP-N-acetylneuraminic acid hydroxylase gene Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11399 11404
14. Chou H.-H., Hayakawa T., Diaz S., Krings M., Indriati E., Leakey M., Paabo S., Satta Y., Takahata N., Varki A., Inactivation of CMP-N- acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution Proceedings of the National Academy of Sciences of the United States of America 2002 99 18 11736 11741
15. Varki A., Altheide T. K., Comparing the human and chimpanzee genomes: searching for needles in a haystack Genome Research 2005 15 12 1746 1758
16. Malykh Y. N., Schauer R., Shaw L., N-Glycolylneuraminic acid in human tumours Biochimie 2001 83 7 623 634
17. Vamecq J., Mestdagh N., Henichart J.-P., Poupaert J., Subcellular distribution of glycolyltransferases in rodent liver and their significance in special reference to the synthesis of N-glycolylneuraminic acid Journal of Biochemistry 1992 111 5 579 583
18. Hedlund M., Tangvoranuntakul P., Takematsu H., Long J. M., Housley G. D., Kozutsumi Y., Suzuki A., Wynshaw-Boris A., Ryan A. F., Gallo R. L., Varki N., Varki A., N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution Molecular and Cellular Biology 2007 27 12 4340 4346
19. Bardor M., Nguyen D. H., Diaz S., Varki A., Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells Journal of Biological Chemistry 2005 280 6 4228 4237
20. Gabri M. R., Otero L. L., Gomez D. E., Alonso D. F., Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines Journal of Experimental and Clinical Cancer Research 2009 28 1, article no. 146
21. Hedlund M., Padler-Karavani V., Varki N. M., Varki A., Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression Proceedings of the National Academy of Sciences of the United States of America 2008 105 48 18936 18941
22. Varki A., Uniquely human evolution of sialic acid genetics and biology Proceedings of the National Academy of Sciences of the United States of America 2010 107 supplement 2 8939 8946
23. de Len J., Fernndez A., Clavell M., Labrada M., Bebelagua Y., Mesa C., Fernndez L. E., Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4 + CD25 - effector and naturally occurring CD4 + CD25 + regulatory T cells function International Immunology 2008 20 4 591 600
24. Vzquez A. M., Gabri M. R., Hernndez A. M., Alonso D. F., Beausoleil I., Gomez D. E., Prez R., Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides Oncology Reports 2000 7 4 751 756
25. Fuentes D., Avellanet J., Garcia A., Iglesias N., Gabri M. R., Alonso D. F., Vazquez A. M., Perez R., Montero E., Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model Breast Cancer Research and Treatment 2010 120 2 379 389
26. Carr A., Rodrguez E., Arango M. D. C., Camacho R., Osorio M., Gabri M., Carrillo G., Valds Z., Bebelagua Y., Prez R., Fernndez L. E., Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine Journal of Clinical Oncology 2003 21 6 1015 1021
27. Hernndez A. M., Toledo D., Martnez D., Grin T., Brito V., Macas A., Alfonso S., Rondn T., Surez E., Vzquez A. M., Prez R., Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody Journal of Immunology 2008 181 9 6625 6634
28. Alfonso S., Diaz R. M., De La Torre A., Santiesteban E., Aguirre F., Prez K., Rodrguez J. L., Barroso M. D. C., Hernndez A. M., Toledo D., Gabri M. R., Alonso D. F., Viada C., Gmez R. E., Surez E., Vazquez A. M., Perez R., Macias A. E., 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients Cancer Biology and Therapy 2007 6 12 1847 1852
29. Guthmann M. D., Castro M. A., Cinat G., Venier C., Koliren L., Bitton R. J., Vzquez A. M., Fainboim L., Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients Journal of Immunotherapy 2006 29 2 215 223
30. Osorio M., Gracia E., Rodrguez E., Saurez G., Arango M. D. C., Noris E., Torriella A., Joan A., Gmez E., Anasagasti L., Gonzlez J. L., Melgares M. D. L. A., Torres I., Gonzlez J., Alonso D., Rengifo E., Carr A., Prez R., Fernndez L. E., Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study Cancer Biology and Therapy 2008 7 4 488 495
31. Carr A., Mullet A., Mazorra Z., Vazquez A. M., Alfonso M., Mesa C., Rengifo E., Perez R., Fernandez L. E., A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors Hybridoma 2000 19 3 241 247
32. Nakarai H., Chandler P. J., Kano K., Morton D. L., Irie R. F., Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma International Archives of Allergy and Applied Immunology 1990 91 3 323 328
33. Marquina G., Waki H., Fernandez L. E., Kon K., Carr A., Valiente O., Perez R., Ando S., Gangliosides expressed in human breast cancer Cancer Research 1996 56 22 5165 5171
34. Tangvoranuntakul P., Gagneux P., Diaz S., Bardor M., Varki N., Varki A., Muchmore E., Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid Proceedings of the National Academy of Sciences of the United States of America 2003 100 21 12045 12050
35. van Cruijsen H., Ruiz M., van der Valk P., de Gruijl T. D., Giaccone G., Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer BMC Cancer 2009 9, article no. 180
36. Scursoni A. M., Galluzzo L., Camarero S., Pozzo N., Gabri M. R., De Acosta C. M., Vzquez A. M., Alonso D. F., De Davila M. T.G., Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry Pediatric and Developmental Pathology 2010 13 1 18 23
37. Diaz Y., Gonzalez A., Lopez A., Perez R., Vazquez A. M., Montero E., Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma Cancer Immunology, Immunotherapy 2009 58 7 1117 1128
38. Labrada M., Clavell M., Bebelagua Y., De Len J., Alonso D. F., Gabri M. R., Veloso R. C., Vrez V., Fernndez L. E., Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy Expert Opinion on Biological Therapy 2010 10 2 153 162
39. Kaste S. C., Dome J. S., Babyn P. S., Graf N. M., Grundy P., Godzinski J., Levitt G. A., Jenkinson H., Wilms tumour: prognostic factors, staging, therapy and late effects Pediatric Radiology 2008 38 1 2 17
40. Vazquez A. M., Alfonso M., Lanne B., Karlsson K.-A., Carr A., Barroso O., Fernandez L. E., Rengifo E., Lanio M. E., Alvarez C., Zeuthen J., Perez R., Generation of a murine monoclonal antibody specific for N- glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids Hybridoma 1995 14 6 551 556
41. Bansal A. S., Abdul-Karim B., Malik R. A., Goulding P., Pumphrey R. S. H., Boulton A. J. M., Holt P. L. J., Wilson P. B., IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls Journal of Clinical Pathology 1994 47 4 300 302
42. Niebroj-Dobosz I., Janik P., Kwieciski H., Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes European Journal of Neurology 2004 11 1 13 16
43. Kusunoki S., Kaida K.-I., Ueda M., Antibodies against gangliosides and ganglioside complexes in Guillain-Barr syndrome: new aspects of research Biochimica et Biophysica Acta 2008 1780 3 441 444
44. Willison H. J., Gangliosides as targets for autoimmune injury to the nervous system Journal of neurochemistry 2007 103 supplement 1 143 149
45. Greenwood D. L. V., Gitlits V. M., Alderuccio F., Sentry J. W., Toh B.-H., Autoantibodies in neuropsychiatric lupus Autoimmunity 2002 35 2 79 86
46. Merrick J. M., Zadarlik K., Milgrom F., Characterization of the Hanganutziu-Deicher (serum-sickness) antigen as gangliosides containing N-glycolylneuraminic acid International Archives of Allergy and Applied Immunology 1978 57 5 477 480
47. Kasukawa R., Kano K., Bloom M. L., Milgrom F., Heterophile antibodies in pathologic human sera resembling antibodies stimulated by foreign species sera Clinical and Experimental Immunology 1976 25 1 122 132
48. Alfonso M., Daz A., Hernndez A. M., Prez A., Rodrguez E., Bitton R., Prez R., Vzquez A. M., An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients Journal of Immunology 2002 168 5 2523 2529
49. Neninger E., Daz R. M., De La Torre A., Rives R., Daz A., Saurez G., Gabri M. R., Alonso D. F., Wilkinson B., Alfonso A. M., Combet T., Prez R., Vzquez A. M., Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial Cancer Biology and Therapy 2007 6 2 145 150 (Pubitemid 46641614)
50. Daz A., Alfonso M., Alonso R., Saurez G., Troche M., Catal M., Daz R. M., Prez R., Vzquez A. M., Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides Clinical Immunology 2003 107 2 80 89
51. Talavera A., Eriksson A., kvist M., Lpez-Requena A., Fernndez-Marrero Y., Prez R., Moreno E., Krengel U., Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody Molecular Immunology 2009 46 16 3466 3475
52. Lang J. M., Andrei A.-C., McNeel D. G., Prioritization of cancer antigens: keeping the target in sight Expert Review of Vaccines 2009 8 12 1657 1661
53. Katsumura Y., Yasunaga H., Imamura T., Ohe K., Oyama H., Relationship between risk information on total colonoscopy and patient preferences for colorectal cancer screening options: analysis using the Analytic Hierarchy Process BMC Health Services Research 2008 8
54. Dolan J. G., Iadarola S., Risk communication formats for low probability events: an exploratory study of patient preferences BMC Medical Informatics and Decision Making 2008 8, article no. 14
55. Bhushan N., Rai K., Strategic Decision Making: Applying the Analytic Hierarchy Process 2004 London, UK Springer
56. Olson W. C., Heston W. D. W., Rajasekaran A. K., Clinical trials of cancer therapies targeting prostate-specific membrane antigen Reviews on Recent Clinical Trials 2007 2 3 182 190
57. Forman E. H., Gass S. I., The analytic hierarchy processAn exposition Operations Research 2001 49 4 469 486
58. Bot A., The landmark approval of provenge, what it means to immunology and in this issue: the complex relation between vaccines and autoimmunity International Reviews of Immunology 2010 29 235 238